Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Padsevonil - UCB

Drug Profile

Padsevonil - UCB

Alternative Names: UCB-0942; UCB1415943-000

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Imidazoles; Pyrrolidinones; Small molecules; Thiadiazoles
  • Mechanism of Action GABA A receptor agonists; Neurotransmitter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in Japan (PO, Tablet)
  • 08 Feb 2022 UCB pharma terminates a phase II trial in Epilepsy (Adjunctive treatment, Treatment-resistant) (PO) in Netherlands, Germany, Belgium, Hungary, Italy, Spain, Bulgaria (EudraCT2015-001268-20) (NCT02625090)
  • 03 Jan 2022 UCB Biopharma terminates phase II/III trial in drug-resistant Epilepsy in USA, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia,Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Lithuania, Mexico, Poland, Romania, Serbia, Slovakia, Spain, Turkey and United Kingdom
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top